EQ News

(NASDAQ:EQ) eQ Plc Managers' Transactions 1 September 2025 at 3:00 p.m.

(NASDAQ:EQ) LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium to Participate in the Cantor Global Healthcare Conference 2025

eQ Plc Managers' Transactions 14 August 2025 at 4:00 p.m.

LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium, Inc. (“Equillium” or the “Company”) (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it has entered into a definitive securities purchase agreement with leading healthcare investors that will provide up to $50 million in gross proceeds to Equillium. The private placement is comprised of (i) an initial upfront financing of approximately $30 million in gross proce

LA JOLLA, Calif.--(BUSINESS WIRE)-- #Bitcoin--Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced a strategic expansion to integrate a cryptocurrency treasury reserve strategy as part of its broader financial and growth objectives. “As we are actively evaluating strategic options for the company, I am pleased to announce we have expanded our treasury strategy to include digital currencies for the diversif

Equillium's itolizumab showed improved longer-term outcomes in aGVHD despite missing primary endpoints. FDA feedback on potential Accelerated Approval is expected in May.